Campylobacteriosis following immunosuppression for immune checkpoint inhibitor-related toxicity

Campylobacteriosis following immunosuppression for immune checkpoint inhibitor-related toxicity

Five patients receiving checkpoint inhibitor immunotherapy (CPI) under our care across two cancer centers over a 12-month period have subsequently developed campylobacterosis. All had received immune-suppressive treatment for CPI-related colitis in the weeks or months preceding the detection of Camp...

Full description

Bibliographic Details
Main Author:	Heather Shaw
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-07-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/8/2/e000577.full

Similar Items

Management of Immune Checkpoint Inhibitor-Related Rheumatological Toxicities
by: Pak Yui Fong, et al.
Published: (2020-07-01)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
by: Ya Xu, et al.
Published: (2020-10-01)

Management of Dermatologic Toxicities Related to Immune Checkpoint Inhibitors
by: Xiaoyan SI, et al.
Published: (2019-10-01)

Management of Immune Checkpoint Inhibitor Toxicities
by: Durrechou Q, et al.
Published: (2020-09-01)

Immune Checkpoint Inhibitor–Related Cardiovascular Toxicity in Lung Cancer
by: Lova Sun, MD, et al.
Published: (2019-12-01)

Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis
by: Jennifer Cautela, et al.
Published: (2020-07-01)

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
by: Katarina Hradska, et al.
Published: (2021-08-01)

Management of Gastrointestinal Toxicity from Immune Checkpoint Inhibitor
by: Marta Rocha, et al.
Published: (2018-12-01)

Management of pulmonary toxicity associated with immune checkpoint inhibitors
by: Myriam Delaunay, et al.
Published: (2019-11-01)

Impact of the gut microbiota on immune checkpoint inhibitor-associated toxicities
by: Rossanna C. Pezo, et al.
Published: (2019-09-01)

292 Immune checkpoint inhibitor induced overlapping cardiac and neuromuscular toxicities: Highlight of early diagnosis, early initiation of immunosuppressive therapy and multidisciplinary management
by: Robert O’Neill, et al.
Published: (2020-11-01)

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
by: Douglas B. Johnson, et al.
Published: (2019-05-01)

Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders
by: Michelle Coureau, et al.
Published: (2020-05-01)

How we treat neurological toxicity from immune checkpoint inhibitors
by: Lavinia Spain, et al.
Published: (2019-07-01)

Myocardial and Pericardial Toxicity Associated With Immune Checkpoint Inhibitors in Cancer Patients
by: Johnny Chahine, MD, et al.
Published: (2020-02-01)

Immune checkpoint inhibitor-related acral vasculitis
by: Thibault Comont, et al.
Published: (2018-11-01)

Food, fish and campylobacteriosis
by: Alejandro de Jesús Cortés-Sánchez
Published: (2020-10-01)

Tracing the source of campylobacteriosis.
by: Daniel J Wilson, et al.
Published: (2008-09-01)

Immune Checkpoint Inhibitor Therapy Associated Hypophysitis
by: Moeber Mahzari, et al.
Published: (2015-03-01)

Immune Checkpoint Inhibitor Therapy Associated Hypophysitis
by: Moeber Mahzari, et al.
Published: (2015-01-01)

CCND1 Amplification Contributes to Immunosuppression and Is Associated With a Poor Prognosis to Immune Checkpoint Inhibitors in Solid Tumors
by: Yu Chen, et al.
Published: (2020-08-01)

Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature
by: Nikhil Agrawal, et al.
Published: (2019-03-01)

Immune Checkpoint Inhibitor Toxicity in Head and Neck Cancer: From Identification to Management
by: Haiyang Wang, et al.
Published: (2019-10-01)

Immune-mediated adverse rheumatic reactions following administration of immune checkpoint inhibitors
by: I. V. Menshikova, et al.
Published: (2020-09-01)

Immune Checkpoints: Novel Therapeutic Targets to Attenuate Sepsis-Induced Immunosuppression
by: Margaret A. McBride, et al.
Published: (2021-02-01)

Cardiac Adverse Events Related to Immune Checkpoint Inhibitors∗
by: Dorothy M. Gujral, PhD, et al.
Published: (2020-02-01)

Immune Checkpoint Inhibitors and the Heart
by: Diana Larisa Mocan-Hognogi, et al.
Published: (2021-09-01)

The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
by: Xiao-Hui Jia, et al.
Published: (2020-12-01)

Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis
by: Hamzah Abu-Sbeih, et al.
Published: (2019-04-01)

Rheumatic Immune-related Adverse Events and Treatment of Immune Checkpoint Inhibitors
by: ZHANG Xue, et al.
Published: (2020-11-01)

Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors
by: Sarah Abou Alaiwi, et al.
Published: (2020-06-01)

Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors
by: Michael F. Gowen, et al.
Published: (2018-04-01)

Campylobacteriosis, Eastern Townships, Québec
by: Sophie Michaud, et al.
Published: (2004-10-01)

Human Campylobacteriosis in Developing Countries
by: Akitoye O. Coker, et al.
Published: (2002-03-01)

Immune Checkpoint Inhibitors New Insights and Recent Progress
Published: (2023)

Tumour-immune dynamics with an immune checkpoint inhibitor
by: Elpiniki Nikolopoulou, et al.
Published: (2018-06-01)

Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis
by: Florentia Dimitriou, et al.
Published: (2021-06-01)

Immuno-related endocrinopathy in patients treated with immune checkpoint inhibitors
by: D. I. Yudin, et al.
Published: (2020-07-01)

Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside
by: Antonio G. Solimando, et al.
Published: (2020-04-01)

Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections
by: Minya Lu, et al.
Published: (2020-03-01)

Cannot write session to /tmp/vufind_sessions/sess_pqbhjnq7drp2ld0qlmp02unoie